X

Trial Profile

A Randomised Controlled Comparison of Campath-Tacrolimus vs IL2R MoAb-Tacrolimus/Mycophenolate Mofetil in Kidney Transplantation

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alemtuzumab (Primary) ; Daclizumab (Primary) ; Mycophenolate mofetil; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use
Acronyms CamTac

Most Recent Events

09 Feb 2012 Actual end date (Dec 2008) added as reported by ISRCTN: Current Controlled Trials.
09 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
02 Sep 2009 Results reported at ESOT 2009.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com